
Cartoon – Healthcare Industry Today



It’s customary in the nation’s capital to hail members of the incoming administration by telling everyone in town how close you are to them. So many in conservative Washington lobbying circles and elsewhere are busy touting their relationships with President-elect Donald Trump and his advisers.
There’s a benefit to proximity to power, especially now. At a time when nobody really knows how the Trump administration will regulate drugs and medical devices, fund scientific research, or repeal or replace the Affordable Care Act, relationships with the newcomers are viewed as critical to getting one’s issues on the table.
Donations don’t hurt, either.
Trump’s transition team is a moving train, so influencers are likely to jump aboard fast. Here’s STAT’s look at people and organizations in health care and science who are likely to have influence with a Trump presidency — and who else might benefit.

NYC hedge fund Glenview Capital Management, headed by Larry Robbins, has pulled back sharply on its healthcare investments despite its usual emphasis on the industry, Modern Healthcare reported. The hedge fund overall reduced its shares in 11 of 16 healthcare companies during the first quarter, including Aetna, Anthem, Cigna and Humana, which await uncertain state and federal regulatory approval for mergers.